uMotif: $25.5m investment funding
Clinical trial technology company uMotif has announced receipt of an additional $25.5m in investment funding. The funds reportedly will be used to scale up the company’s clinical research platform.
Steve Rosenberg, CEO of uMotif, said, “I truly believe that clinical research must put patients first, delivering more engaging research studies. With this investment from Athyrium I'm excited to grow our global capabilities to better serve our sponsors, partners and – most importantly – the patients we help take part in research."
